Characterising methamphetamine/amphetamine use among opioid agonist therapy‐seeking adults with prescription‐type opioid use disorder in Canada
Drug and Alcohol Review · 2024
DOI: 10.1111/dar.13863 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Drug and Alcohol Review, 2024. Verfasst von Jenna Langlois und 5 weiteren Autor:innen. Beteiligte Einrichtung: British Columbia Centre on Substance Use, Vancouver, Canada. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Methamphetamine, Opiate Substitution Treatment, Amphetamine-Related Disorders. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Canadian Research Initiative on Substance Misuse, Canadian Institutes of Health Research.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Introduction
There has been a significant increase in methamphetamine/amphetamine use in North America, particularly among people who use opioids. Despite its association with several negative health consequences, the population of people who use methamphetamine/amphetamine with opioids is not well characterised. The aim of this study was to investigate correlates of methamphetamine/amphetamine use among adults with prescription‐type opioid use disorder (POUD) starting methadone or buprenorphine/naloxone as part of a pragmatic randomised treatment trial in Canada.
Methods
Multivariable logistic regression analyses were used to determine factors associated with baseline methamphetamine/amphetamine use (measured by urine drug test [UDT]) among participants of a pan‐Canadian pragmatic trial conducted between 2017 and 2020 comparing supervised methadone versus flexible take‐home dosing buprenorphine/naloxone models of care in people with POUD (e.g., licit or illicit, including fentanyl, prescribed or not).
Results
The sample included 269 participants, of which 142 (52.8%) had positive baseline methamphetamine/amphetamine UDT. In the multivariable model, positive fentanyl UDT (adjusted odds ratio [AOR] 13.21, 95% confidence interval [CI] 6.45, 28.30), non‐fatal overdose in the last 6 months (AOR 2.26, CI 1.01, 5.17) and a lifetime history of opioid agonist therapy exposure prior to study entry (AOR 2.30, CI 1.09, 4.87) remained positively associated with baseline methamphetamine/amphetamine use. Discussion and Conclusions In this sample of people with POUD, methamphetamine/amphetamine use was associated with markers of complex and severe OUD, including overdose risk. This suggests the need for targeted interventions to optimise treatment outcomes and prevent future overdoses in this population. Clinical Trial Registration: Available at: ClinicalTrials.gov NCT03033732.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- British Columbia Centre on Substance Use, Vancouver, Canada.
- Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
- Research Centre, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
- Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, Canada.
- Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Canada.
- Department of Pharmacology and Toxicology, Faculty of Medicine, Medical Sciences Building, University of Toronto, Toronto, Canada.
ORCID-Profile: Nadia Fairbairn, Didier Jutras-Aswad, M Eugenia Socías
Förderung
- CIHR
- Canadian Research Initiative on Substance Misuse
- Canadian Institutes of Health Research
Zitieren
APA
Langlois, J., Fairbairn, N., Jutras-Aswad, D., Le Foll, B., Lim, R., & Socías, M. E. (2024). Characterising methamphetamine/amphetamine use among opioid agonist therapy‐seeking adults with prescription‐type opioid use disorder in Canada. Drug and Alcohol Review. https://doi.org/10.1111/dar.13863
Vancouver
Langlois J, Fairbairn N, Jutras-Aswad D, Le Foll B, Lim R, Socías ME. Characterising methamphetamine/amphetamine use among opioid agonist therapy‐seeking adults with prescription‐type opioid use disorder in Canada. Drug and Alcohol Review. 2024. doi:10.1111/dar.13863
BibTeX
@article{Langlois2024,
author = {Langlois, Jenna and Fairbairn, Nadia and Jutras-Aswad, Didier and Le Foll, Bernard and Lim, Ron and Socías, M Eugenia},
title = {Characterising methamphetamine/amphetamine use among opioid agonist therapy‐seeking adults with prescription‐type opioid use disorder in Canada},
journal = {Drug and Alcohol Review},
year = {2024},
doi = {10.1111/dar.13863}
}
EUVIMED